TBPH

TBPH

USD

Theravance Biopharma Inc. Ordinary Shares

$10.610-0.170 (-1.577%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$10.780

Hoch

$10.780

Tief

$10.520

Volumen

0.00M

Unternehmensfundamentaldaten

Marktkapitalisierung

530.5M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.28M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $7.44Aktuell $10.610Hoch $11.82

Ähnliche Nachrichten

PR Newswire

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3...

Mehr anzeigen
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress
PR Newswire

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first...

Mehr anzeigen
Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR Newswire

Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of...

Mehr anzeigen
Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress
PR Newswire

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on...

Mehr anzeigen
Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025